GlassScriptPhysician profile
Kenneth Morford
NPI 1083059984
$977.05
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $152 · 2021: $152 · 2022: $28.41 · 2023: $68.77 · 2024: $44.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $113.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.57 | 2019-2020 | |
| Indivior INC. | $194.49 | 2019-2024 | Sublocade |
| Abbvie INC. | $151.90 | 2019-2021 | |
| Pfizer INC. | $98.85 | 2019-2023 | |
| Orexo US, INC. | $95.87 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.44 | 2019-2020 | |
| Gilead Sciences, INC. | $47.14 | 2021-2022 | |
| Allergan, INC. | $44.21 | 2019-2020 | |
| Alkermes, INC. | $31.01 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $15.03 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.93 | 2024 | Relexxii |
| Takeda Pharmaceuticals U.S.A., INC. | $10.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Morford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.